Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.38 |
| ▸ | LPL | P06858 | 12/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299346 | 1.00 | F11 (0.38) | F11LIPGLPLPGRROCK1 | |
| SCHEMBL16831298 | 0.88 | F11 (0.38) | F11LIPGLPLROCK1CA1 | |
| SCHEMBL12501640 | 0.82 | LPL (0.38) | F11LIPGLPLROCK1CA1 | |
| SCHEMBL22547333 | 0.80 | PDPK1 (0.46) | LIPGLPLROCK1CA1CA2 | |
| SCHEMBL17042527 | 0.80 | F11 (0.37) | F11LIPGLPLPGRROCK1 | |
| SCHEMBL31394481 | 0.80 | BACE1 (0.37) | LIPGLPLROCK1CA1CA2 | |
| SCHEMBL12501513 | 0.80 | F11 (0.38) | F11LIPGLPLROCK1CA1 | |
| SCHEMBL12501638 | 0.80 | F11 (0.38) | F11LIPGLPLROCK1CA1 | |
| SCHEMBL22497743 | 0.79 | LIPG (0.37) | LIPGLPLROCK1CA1CA2 | |
| SCHEMBL15912452 | 0.78 | LPL (0.37) | F11LIPGLPLROCK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4620469-A2 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4175719-B1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4175719-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-06-02 | — | — | US | disclosed |
| US-20170369497-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | disclosed |
| US-9695180-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695180-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695180-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| CN-104016979-B | Substituted cyclic compound as well as use method and application thereof | 广东东阳光药业有限公司 | 2017-05-03 | — | — | CN | disclosed |
| US-20160009720-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| US-20160009720-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| US-20160009720-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2016007736-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016007736-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009720-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM1B, KDM2A, KDM1A | F11 4611/4885LIPG 3687/4885LPL 4054/4885 |
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | F11 2654/4885LIPG 3907/4885LPL 4713/4885 |
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | F11 2654/4885LIPG 3907/4885LPL 4713/4885 |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | F11 2654/4885LIPG 3907/4885LPL 4713/4885 |
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | F11 2654/4885LIPG 3907/4885LPL 4713/4885 |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | F11 2654/4885LIPG 3907/4885LPL 4713/4885 |
| US-20170369497-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM5A | F11 4258/4885LIPG 3802/4885LPL 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.